key: cord-0885951-iyfbnvno
authors: Lindner, Andreas K.; Nikolai, Olga; Rohardt, Chiara; Burock, Susen; Hülso, Claudia; Bölke, Alisa; Gertler, Maximilian; Krüger, Lisa J.; Gaeddert, Mary; Tobian, Frank; Lainati, Federica; Seybold, Joachim; Jones, Terry C.; Hofmann, Jörg; Sacks, Jilian A.; Mockenhaupt, Frank P.; Denkinger, Claudia M.
title: Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab
date: 2021-02-11
journal: Eur Respir J
DOI: 10.1183/13993003.04430-2020
sha: e7356cdf3921e91e64a77e3f6cbe1668612cf899
doc_id: 885951
cord_uid: iyfbnvno

Professional nasal sampling is a reliable alternative to nasopharyngeal sampling when using a WHO-listed SARS-CoV-2 antigen-detecting rapid test. This less invasive method can be performed with less training and can facilitate rapid scaling of antigen testing strategies.

Correspondence: Claudia M. Denkinger, Division of Clinical Tropical Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany. E-mail: claudia.denkinger@uniheidelberg.de Take-Home Message: Professional nasal sampling is a reliable alternative to nasopharyngeal sampling when using a WHO-listed SARS-CoV-2 antigen-detecting rapid test. This less invasive method can be performed with less training and can facilitate rapid scaling of antigen testing strategies.

Antigen-detecting rapid diagnostic tests (Ag-RDTs) are likely to play a substantial role in innovative testing strategies for SARS-CoV-2 [1, 2] . Currently, most Ag-RDTs require nasopharyngeal (NP) sampling performed by qualified healthcare professionals. Nasal sampling would enable scaling of antigen testing strategies. The term nasal sampling is often not used uniformly but can be differentiated in anterior nasal sampling (entire absorbent tip of the swab, usually 1 to 1.5 cm, inserted into nostril), and nasal mid-turbinate (as described below) [3] .

We conducted a prospective diagnostic accuracy study with the objective to directly compare the performance of professional-collected nasal mid-turbinate (NMT) versus NP swab, using a WHOlisted SARS-CoV-2 Ag-RDT. The reference standard was RT-PCR collected from a combined NP/oropharyngeal (OP) swab. The study was continued until 30 positive NP swab samples according to Ag-RDT were obtained, which is the minimum recommended by the WHO Emergency Use Listing Procedure to demonstrate sample type equivalency [4] . This manufacturer-independent study was conducted in partnership with the Foundation of Innovative New Diagnostics (FIND), the WHO collaborating centre for COVID-19 diagnostics.

Adults at high risk for SARS-CoV-2 infection according to clinical suspicion who attended the ambulatory SARS-CoV-2 testing facility of Charité University Hospital Berlin, Germany, were enrolled from 11-18 November 2020. Participants were excluded if either of the swabs for the Ag-RDT or the RT-PCR reference standard could not be collected.

Participants had to blow once the nose with a tissue. Afterwards, a NMT-sample was collected on both sides of the nose, using the specific nasal swab provided in the test kit of the manufacturer, according to the instructions for use, which also correspond to the U.S. CDC instructions [3] . Briefly, while tilting the patient's head back 70 degrees, the swab was inserted about 2cm into each nostril, parallel to the palate until resistance was met at turbinates, then rotated 3-4 times against the nasal walls. Subsequently, a separate NP-swab (provided in the manufacturer test kit) for the Ag-RDT and a combined OP/NP-swab (eSwab from Copan placed in 1ml Amies medium) as per institutional recommendations for RT-PCR were taken from different sides of the nose.

The Ag-RDT evaluated was the STANDARD Q COVID-19 Ag Test (SD Biosensor, Inc. Gyeonggi-do, Korea; henceforth called STANDARD Q) [5] . Study procedures followed the same process as described in the prior study by Lindner et al [6] . While the test is commercially available as NPsampling kit, the nasal-sampling kit is currently available for 'research use only' by the manufacturer.

The instructions for use of the two test kits showed differences, with a more elaborate extraction process (stirring the swab at least 10 vs. 5 times) and a higher volume of extracted specimen (4 vs. 3 drops) used for testing of nasal samples.

Of 181 patients invited, 180 (99.4%) consented to participate. One patient was excluded as both swabs for the Ag-RDT could not be obtained. The average age of participants was 36. specificity was 99.3% (95% CI 96.0-100). In patients with high viral load (>7.0 log 10 SARS-CoV2 RNA copies/swab), the sensitivity of the Ag-RDT with NMT-sampling was 100% (19/19 PCR positives detected; 95% CI 83.9-100) and 94.7% (18/19 PCR positives detected; 95% CI 76.4-99.7) with NPsampling. In contrast, the Ag-RDT more frequently did not detect patients with lower viral load or with symptoms >7 days (Table 1) , as commonly observed in studies on Ag-RDTs [7, 8] .

The strengths of the study are the standardized sampling methods, two independent blinded readers and an additional semi-quantitative assessment of Ag-RDT results. The cohort was representative, judging from the comparable sensitivity observed in the recent independent validation study of STANDARD Q (sensitivity 76.6%; 95% CI 62.8-86.4) [9] . The study is limited as it was performed in a single centre. Theoretically, the previous NMT sample collection could have negatively influenced the test result of the NP sample in patients with a low viral load.

In conclusion, this study demonstrates that sensitivity of a WHO-listed SARS-CoV-2 Ag-RDT using professional nasal-sampling kit is at least equal to that of NP-sampling kit, although confidence intervals overlap. Of note, differences in the instructions for use of the test procedures could have contributed to different sensitivities. NMT-sampling can be performed with less training, reduces patient discomfort, and enables scaling of antigen testing strategies. Additional studies of patient self-sampling should be considered to further facilitate scale-up of Ag-RDT testing [6] . 1 Antigen-detecting RDT results with a professional-collected NMT swab and NP swab in RT-PCR positive patients from combined OP/NP swab. CT-values and viral load (in descending order) of the paired RT-PCR samples are shown, as well as the duration of symptoms per patient. The positive percent agreement between NMT and NP samples on Ag-RDT, and the respective sensitivities compared to RT-PCR are shown.

No., patient number; SD Q, STANDARD Q COVID-19 Ag Test (SD Biosensor); Ag-RDT, antigen-detecting rapid diagnostic test; NMT, nasal mid-turbinate; NP, nasopharyngeal; OP, oropharyngeal; CT, cycle threshold; RT-PCR, reverse 

European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK

European Centre for Disease Prevention and Control. Surveillance of COVID-19 at long-term care facilities in the EU/EEA

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19

WHO. Instructions and requirements for Emergency Use Listing (EUL) submission: In vitro diagnostics detecting SARS-CoV-2 nucleic acid and rapid diagnostics tests detecting SARS-CoV-2 antigens

COVID-19 Ag STANDARDTM Q COVID-19 Ag Test 2020

Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-collected nasopharyngeal swab

Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers

Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial

Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-ofcare diagnostics for SARS-CoV-2

The study was supported by FIND, Heidelberg University Hospital and Charité University Hospital internal funds, as well as a grant of the Ministry of Science, Research and the Arts of Baden-Württemberg, Germany. FIND provided input on the study design, and data analysis in collaboration with the rest of the study team.

Author contributions: AKL, LJK, FL and CMD designed the study and developed standard operating procedures. AKL and ON implemented the study design, enrolled patients, performed laboratory work and led the writing of the manuscript. FPM and JS coordinated and supervised the study site. CR, SB, CH, AB enrolled patients. MGe coordinated the testing facility. MGa and FT led the data analysis. TCJ and JH were responsible for PCR testing and contributed to the interpretation of the data. JAS supported the study design setup and the interpretation of the data. All authors have reviewed the manuscript.Data availability: All raw data and analysis code are available upon a request to the corresponding author.